Ira Pastor Comments
On a few past episodes, we have journeyed into the area psychedelic therapies, which broadly refers to therapeutic practices involving psychedelic drugs. In psychedelic therapy, in contrast to conventional psychiatric medication taken by the patient regularly or as-needed, patients generally remain in an extended psychotherapy session during the acute psychedelic activity with additional sessions both before and after in order to help integrate experiences with the drug.
Psilocybin is a naturally occurring psychedelic pro-drug compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms, which has mind-altering effects similar, in some aspects, to those of LSD, mescaline, and DMT, and include euphoria, visual and mental changes in perception, and spiritual experiences.
Dr. Ekaterina Malievskaia:
Dr. Ekaterina Malievskaia MD, is Chief Innovation Officer, Co-founder, and Research and Development Director, at COMPASS Pathways, a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, currently researching how psilocybin therapy could help people with disorders such as treatment-resistant depression, as well as other areas or improving mental well-being.
Dr. Malievskaia received her medical degree from St Petersburg Medical Academy in St Petersburg, Russia. After her Internal Medicine residency training, she completed an Environmental Medicine Fellowship at Mount Sinai School of Medicine and received her MSc in Public Health from New York University Medical School. She worked in private practice, academic medicine and public health for more than 15 years in the greater New York area. She was a Clinical Instructor of Medicine at Mount Sinai School of Medicine, as well as a Research Professor at City University of New York.
After moving to London in 2011, Dr. Malievskaia worked in global health and medical philanthropy, focusing on improving outcomes in maternal and child health.
She founded COMPASS Pathways with her husband George Goldsmith in 2016, having experienced at first hand the challenges in accessing evidence-based and effective mental health care for a family member.
On this ideaXme episode we will hear from Dr. Malievskaia about:
Her background; how she became interested in medicine, public health, and how she has arrived at the epicenter of psychedelic therapeutics and clinical medicine. A discussion about the ethnomedicinal (magic mushrooms) and early 20th Century pharmacological development history of Psilocybin. A discussion of the indication of treatment-resistant depression. A discussion of their Phase I trial evaluating the safety of COMP360 (psilocybin) for the treatment of patients with depression at King’s College London.
Credits: Ira Pastor interview video, text, and audio.
Follow Ira Pastor on Twitter:@IraSamuelPastor
If you liked this interview, be sure to check out our interview on psychedelic drugs!
Follow ideaXme on Twitter:@ideaxm
Find ideaXme across the internet including on iTunes, SoundCloud, Radio Public, TuneIn Radio ,I Heart Radio, Google Podcasts, Spotify and more.
ideaXme is a global podcast, creator series and mentor programme. Our mission: Move the human story forward!™ ideaXme Ltd.